小儿狼疮肾炎的诊疗进展

doi:10.3969/j.issn.1671-7171.2018.02.027

摘要
图/表
参考文献
相关文章 (15)

[1] Fatemi A,Matinfar M,Smiley A.Childhood versus adult-onset systemic lupus erythematosus:long-term outcome and predictors of mortality[J].Clin Rheumatol,2017,36(2):343-350.
[2] 中华医学会儿科学分会肾脏病学组,儿童常见肾脏疾病诊治循证指南(试行)(六):狼疮性肾炎诊断治疗指南[J].中华儿科杂志,2010,48(9):687-690.
[3] Giannico G,Fogo AB.Lupus nephritis:is the kidney biopsy currently necessary in the management of lupus nephritis [J].Clin J Am Soc Nephrol,2013,8(1):138-145.
[4] Koutsonikoli A,Trachana M,Farmaki E,et al.Novel biomarkers for the assessment of paediatric systemic lupus erythematosus nephritis[J].Clin Exp Immunol,2017,188(1):79-85.
[5] Wakiguchi H,Takei S,Kubota T,et al.Treatable renal disease in children with silent lupus nephritis detected by baseline biopsy:association with serum C3 levels[J].Clin Rheumatol,2017,36(2):433-437.
[6] Smith EM,Jorgensen AL,Midgley A,et al.International validation of a urinary biomarker panel for identification of active lupus nephritis in children[J].Pediatr Nephrol,2017,32(2):283-295.
[7] Reis PC.Multicenter prospective study on the role of urinary HER2 as a lupus nephritis biomarker[J].Arthritis Rheumatol,2016,68:1727-1728.
[8] Kazyra I.Renal expression of VEGF,TGF1β,Ki-67,CD 68 in children with glomerulopathies[J].Pediatr Nephrol,2016,31(10):1818-1819.
[9] Patel M,Oni L,Midgley A,et al.Increased concentration of plasma TNFR1 and TNFR2 in paediatric lupus nephritis[J].Lupus,2016,25(9):1040-1044.
[10] Abulaban KM,Fall N,Nunna R,et al.Relationship of cell-free urine MicroRNA with lupus nephritis in children[J].Pediatr Rheumatol Online J,2016,14(1):4.
[11] Wenderfer SE,Ruth NM,Brunner HI.Advances in the care of children with lupus nephritis[J].Pediatr Res,2017,81(3):406-414.
[12] Tanaka H,Joh K,Imaizumi T.Treatment of pediatric-onset lupus nephritis:a proposal of optimal therapy[J].Clin Exp Nephrol,2017,21(5):755-763.
[13] Groot N,de Graeff N,Marks SD,et al.European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis:the SHARE initiative[J].Ann Rheum Dis,2017,76(12):1965-1973.
[14] Collado MV,Dorado E,Rausch S,et al.Long-term outcome of lupus nephritis Class II in argentine patients[J].J Clin Rheumatol,2016,22(6):299-306.
[15] Dubrasquet A.Mycophenolic acid area under the curve is associated with therapeutic response in pediatric lupus nephritis[J].Pediatr Nephrol,2017,32(9):1676-1677.
[16] Lau KK,Ault BH,Jones DP,et al.Induction therapy for pediatric focal proliferative lupus nephritis:cyclophosphamide versus mycophenolate mofetil[J].J Pediatr Health Care,2008,22(5):282-288.
[17] Stoll ML,Grubbs JA,Beukelman T,et al.Timing of intravenous cyclophosphamide and long-term outcome in children with proliferative lupus nephritis[J].Pediatr Rheumatol Online J,2017,15(1):79.
[18] Jin SY,Huang DL,Dang XQ,et al.Lupus glomerulonephritis in 788 Chinese children:a multi-centre clinical and histopathological analysis based on 549 renal biopsies[J].Paediatr Int Child Health,2017,37(4):286-291.
[19] Basu B,Roy B,Babu BG.Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis[J].Pediatr Nephrol,2017,32(6):1013-1021.
[20] Hogan J,Godron A,Baudouin V,et al.Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis[J].Pediatr Nephrol,2018,33(1):111-116.
[21] Fujinaga S,Nishino T.Ten-year treatment with mycophenolate mofetil using therapeutic drug monitoring for childhood-onset lupus nephritis in Japan[J].Pediatr Nephrol,2017,32(1):189-190.
[22] Boneparth A,Wenderfer SE,Moorthy LN,et al.Clinical characteristics of children with membranous lupus nephritis:the childhood arthritis and rheumatology research alliance legacy registry[J].Lupus,2017,26(3):299-306.
[23] Boneparth A,Radhakrishna SM,Greenbaum LA,et al.Approach to membranous lupus nephritis:a survey of pediatric nephrologists and pediatric rheumatologists[J].J Rheumatol,2017,44(11):1619-1623.
[24] Hugle B,Silverman ED,Tyrrell PN,et al.Presentation and outcome of paediatric membranous non-proliferative lupus nephritis[J].Pediatr Nephrol,2015,30(1):113-121.
[25] Pereira M.Mycophenolate mofetil is an effective induction therapy agent in childhood-onset pure membranous lupus nephritis[J].Arthritis Rheumatol,2017,69:140-142.
[26] Kise T,Yoshimura H,Fukuyama S,et al.Successful treatment with mycophenolate mofetil and tacrolimus in juvenile severe lupus nephritis[J].Case Rep Pediatr,2015,2015:651803.
[27] Chatzidimitriou A,Trachana M,Gertsi P.The role of tacrolimus in the step-up induction therapy of refractory childhood-onset lupus nephritis[J].Hippokratia,2015,19(4):378.
[28] 王笑秋,殷蕾,茅幼英,等.多靶点治疗儿童狼疮肾炎的疗效观察[J].中华风湿病学杂志,2014,18(9):607-611.
[29] Thakur N,Rai N,Batra P.Pediatric lupus nephritis-review of literature[J].Curr Rheumatol Rev,2017,13(1):29-36.
[30] Aggarwal A,Srivastava P.Childhood onset systemic lupus erythematosus:how is it different from adult SLE[J].Int J Rheum Dis,2015,18(2):182-191.